Taysha Gene Therapies
TSHA
131 hedge funds and large institutions have $290M invested in Taysha Gene Therapies in 2024 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 44 increasing their positions, 28 reducing their positions, and 15 closing their positions.
1,300% more call options, than puts
Call options by funds: $182K | Put options by funds: $13K
87% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 15
57% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 28
10% more funds holding
Funds holding: 119 → 131 (+12)
5.12% more ownership
Funds ownership: 76.6% → 81.72% (+5.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less capital invested
Capital invested by funds: $316M → $290M (-$25.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$20.7M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$12.2M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$10.4M |
| 4 |
State Street
Boston,
Massachusetts
|
+$6.23M |
| 5 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$3.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$13M |
| 2 |
VA
VR Adviser
New York
|
-$12M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$5M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$4.39M |
TSHA Hedge Fund Activity: Q4 2024 in Review
131 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q4 2024, worth a combined $290M — down 8.2% from $316M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new TSHA positions and 15 closed out — a net gain of 13 holders — while 44 added to existing stakes and 28 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $20.7M. The largest seller was RTW Investments, cutting an estimated $13M.
- 131 institutional investors held Taysha Gene Therapies (TSHA) as of Q4 2024, up from 119 in Q3 2024.
- Funds reported $290M of Taysha Gene Therapies stock for Q4 2024, down 8.2% quarter-over-quarter.
- 28 funds opened new Taysha Gene Therapies positions in Q4 2024 and 15 closed out, a net change of +13 holders.
- The largest Taysha Gene Therapies buyer in Q4 2024 was Morgan Stanley, an estimated $20.7M added.
- The largest Taysha Gene Therapies seller in Q4 2024 was RTW Investments, an estimated $13M sold.
Based on aggregated 13F filings for Q4 2024.